|
| Human VEGF-C/Flt4-L Protein (LTP10610) |
|
| LTP10610 |
|
| 100ug |
|
|
$383 In stock |
| the lymphangiogenic factors vascular endothelial growth factor C (VEGFC) and VEGFD are cleaved by thrombin and plasmin, serine proteases generated during hemostasis and wound healing. Genetic studies reveal that platelet enhancement of lymphatic growth after wounding is dependent on the release of VEGFC, but not VEGFD, a finding consistent with high expression of VEGFC in both platelets and avian thrombocytes. |
| Recombinant Human VEGF-C/Flt4-L Protein is expressed from Expi293 with His tag and Avi tag at the C-terminal. It contains Thr103-Arg227. |
|
| VEGF-C/Flt4-L |
|
| Human |
|
| Q6FH59 |
|
| Thr103-Arg227 |
|
| The protein has a predicted MW of 17.1 kDa. Due to glycosylation, the protein migrates to 23-30 kDa based on the Tris-Bis PAGE result. |
|
| Immobilized Human VEGF-C, His Tag at 1ug/ml (100ul/well) on the plate. Dose response curve for Human VEGF R3, hFc Tag with the EC50 of 19.8ng/ml determined by ELISA (QC Test). The affinity constant of 0.29 nM as determined in SPR assay (Biacore T200). See testing image for detail. |
|
| C-His-Avi |
|
| Expi293 |
|
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in 50mM MES, 150mM NaCl (pH 6.0). Normally 8% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in 50mM MES, 150mM NaCI (pH 6.0). |
|
|  |
